Investment Thesis
Company exhibits critical financial distress with negative stockholders' equity of -547.4K (technical insolvency), severe liquidity crisis (0.04x current ratio), and negligible revenue of 22.6K insufficient to cover 2.9M liabilities. Operating cash flow is deeply negative at -459.7K, indicating the current business model is unsustainable and presents extreme solvency risk.
Strengths
- Positive gross margin of 47.9% indicates potential profitability model if revenue scales
- Cash position of 250K provides temporary operational runway
- Pharmaceutical sector offers potential for high-margin products if commercialization succeeds
Risks
- Negative stockholders' equity of -547.4K indicates technical insolvency and balance sheet insolvency
- Current ratio of 0.04x signals severe liquidity crisis and immediate going concern risk
- Operating losses of 637.1K against revenue of only 22.6K demonstrate fundamentally broken unit economics
- Negative operating cash flow of -459.7K shows company is burning cash unsustainably
- Long-term debt of 400K exceeds total assets of 199.4K, creating debt-to-asset crisis
- Zero insider activity in 90 days may indicate abandonment or lack of confidence
Key Metrics to Watch
- Revenue growth trajectory - must increase dramatically from 22.6K base
- Operating cash flow improvement - currently negative 459.7K, must turn positive
- Reduction of operating losses relative to revenue
- Equity restructuring or recapitalization to address negative equity position
- Cash burn rate sustainability against 250K cash position
Financial Metrics
Revenue
22.6K
Net Income
-12.7M
EPS (Diluted)
$-0.16
Free Cash Flow
-486.8K
Total Assets
199.4K
Cash
250.0K
Profitability Ratios
Gross Margin
47.9%
Operating Margin
-2,824.5%
Net Margin
-56,290.2%
ROE
N/A
ROA
-6,369.1%
FCF Margin
-2,158.1%
Balance Sheet & Liquidity
Current Ratio
0.04x
Quick Ratio
0.04x
Debt/Equity
N/A
Debt/Assets
1,464.6%
Interest Coverage
-4.17x
Long-term Debt
400.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T00:21:21.731944 |
Data as of: 2025-09-30 |
Powered by Claude AI